Anti-Fibrinolytic Drugs - South America

South America

In South America, the revenue in the Anti-Fibrinolytic Drugs market is projected to reach US$0.50bn in 2024.
The market is expected to show an annual growth rate (CAGR 2024-2029) of 5.06%, resulting in a market volume of US$0.64bn by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching US$9,858.00m in 2024.
In South America, the market for anti-fibrinolytic drugs is experiencing a surge due to an increased prevalence of bleeding disorders in the region.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market has been steadily growing in South America in recent years.

Customer preferences: Customers in South America are increasingly looking for more effective and affordable treatment options for various medical conditions, including bleeding disorders. Anti-fibrinolytic drugs are becoming a popular choice due to their ability to prevent excessive bleeding by promoting blood clotting.

Trends in the market: Brazil is the largest market for anti-fibrinolytic drugs in South America, accounting for the majority of the region's sales. This can be attributed to the country's large population and high prevalence of bleeding disorders. Argentina and Colombia are also emerging markets for anti-fibrinolytic drugs, as the healthcare infrastructure in these countries continues to improve.

Local special circumstances: One of the major challenges for the anti-fibrinolytic drugs market in South America is the lack of awareness about bleeding disorders and the available treatment options. This is particularly true in rural areas, where access to healthcare is limited. In addition, the high cost of these drugs can be a barrier to access for many patients, especially those without insurance.

Underlying macroeconomic factors: The growing demand for anti-fibrinolytic drugs in South America can be attributed to several macroeconomic factors, including the region's aging population, increasing incidence of bleeding disorders, and improving healthcare infrastructure. In addition, the rise of medical tourism in countries like Brazil is also contributing to the growth of the market. However, the market is also facing challenges due to the economic instability in some countries, which can impact the affordability and accessibility of these drugs for patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.